<DOC>
	<DOC>NCT01390883</DOC>
	<brief_summary>The purpose of this study is to collect and assess information on safety and efficacy of fondaparinux in patients undergoing abdominal surgery in urology, obstetrics and gynecology departments who are at high risk of venous thromboembolism.</brief_summary>
	<brief_title>Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Patients undergoing abdominal surgery in urology, obstetrics and gynecology departments Patients with a history of hypersensitivity to the ingredients of fondaparinux Patients with bleeding (bleeding in important organs, sucn as retroperitoneal bleed) Patients with acute bacterial endocarditis Patients with severe renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>